United States · Bill · S
S. 993 (118th)
Combating Illicit Xylazine Act
Introduced
28 March 2023
Last action
—
Status
Committee on Banking, Housing, and Urban Affairs. Hearings held.
Sponsors
—
Subjects
Discovery layer
Source updated
10 August 2026
Summary
Combating Illicit Xylazine Act This bill criminalizes the illicit use of xylazine. (Xylazine, also known as Tranq , is a sedative that is approved for use in animals. The Drug Enforcement Administration (DEA) has reported an increase in the trafficking of fentanyl mixed with xylazine.) Specifically, the bill establishes criminal penalties for manufacturing, distributing, or dispensing, or possessing with intent to manufacture, distribute, or dispense, xylazine for illicit use (i.e., for use in humans) in accordance with the penalties for schedule III substances (up to 10 years imprisonment or, if death or serious bodily injury occurs, up to 15 years imprisonment, as well as criminal fines). In addition, the DEA must coordinate with the Food and Drug Administration to report on the prevalence of the illicit use of xylazine, including associated supply chains. The bill also declares the illicit use of xylazine as an emerging drug threat.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in Senate (text)
Introduced in Senate · EN · 28 March 2023
Introduced in Senate (PDF)
Introduced in Senate · EN · 28 March 2023
Introduced in Senate
summary · EN · 28 March 2023
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/118th-congress/senate-bill/993
- Open data entity: https://api.congress.gov/v3/bill/118/s/993